Inscrição na biblioteca: Guest
Critical Reviews™ in Immunology

Publicou 6 edições por ano

ISSN Imprimir: 1040-8401

ISSN On-line: 2162-6472

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.3 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.6 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00079 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.24 SJR: 0.429 SNIP: 0.287 CiteScore™:: 2.7 H-Index: 81

Indexed in

CD4+ T Cells in Adoptive Immunotherapy and the Indirect Mechanism of Tumor Rejection

Volume 20, Edição 1, 2000, 40 pages
DOI: 10.1615/CritRevImmunol.v20.i1.20
Get accessGet access

RESUMO

Tumor-specific CD4+ effector T cells often play a decisive role in immunologic tumor rejection, in some cases without evident co-participation of CD8+ T cells. During such CD4+ T-cell-mediated rejection there is often no delectable direct contact between T cells and tumor cells. Optimally prepared, adoptively transferred CD4+ T cells can reject established tumors with great efficiency even when targeted tumor cells express no MHC Class II molecules, implying that recognition of tumor antigen (Ag) occurs via MHC Class II-expressing host antigen-presenting cells (APC) within the tumor. Because consequent rejection also excludes Ag-specific contact between CD4+ T cells and MHC Class IIneg tumor cells, the most critical CD4+ T-cell-mediated event is likely cytokine release, resulting in an accumulation and activation of accessory cells such as tumoricidal macrophages and lymphokine-activated killer cells. Although such an indirect rejection mechanism may appear antithetical to popular strategies centered on CD8+ cytotoxic T cells (CTL), current evidence suggests that even CD8+ T-cell-mediated recognition/rejection often bypasses direct tumor cell contact and is largely cytokine mediated. While CTL are likely to participate prominently in many models of tumor rejection, indirect mechanisms of recognition/ rejection have the theoretical advantage of remaining operative even when individual tumor cells evade direct contact by down-regulating MHC and/or Ag expression

CITADO POR
  1. Visioni Anthony, Zhang Mei, Graor Hallie, Kim Julian, Expansion of melanoma-specific T cells from lymph nodes of patients in stage III: Implications for adoptive immunotherapy in treating cancer, Surgery, 152, 4, 2012. Crossref

  2. Ehlken Hanno, Schadendorf Dirk, Eichmüller Stefan, Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells, International Journal of Cancer, 108, 2, 2004. Crossref

  3. Takamura Yukio, Ikeda Hideyuki, Kanaseki Takayuki, Toyota Minoru, Tokino Takashi, Imai Kohzoh, Houkin Kiyohiro, Sato Noriyuki, Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA), Glia, 45, 4, 2004. Crossref

  4. Homma Sadamu, Komita Hideo, Sagawa Yukiko, Ohno Tsuneya, Toda Gotaro, Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12, Immunology, 115, 4, 2005. Crossref

  5. Knutson K. L., Disis M. L., Tumor antigen-specific T helper cells in cancer immunity and immunotherapy, Cancer Immunology, Immunotherapy, 54, 8, 2005. Crossref

  6. Zhao Yong, Sun Yimin, Niu Zeqing, Li Qinghuan, Peng Jianxiao, Wang Junjie, Langnas Alan N., A Novel Approach to Generate Host Antitumor T Cells: Adoptive Immunotherapy by T cells Maturing in Xenogeneic thymus, Journal of Immunotherapy, 30, 1, 2007. Crossref

  7. Zhao Yangbing, Zheng Zhili, Khong Hung T., Rosenberg Steven A., Morgan Richard A., Transduction of an HLA-DP4–restricted NY-ESO-1–specific TCR into Primary Human CD4+ Lymphocytes, Journal of Immunotherapy, 29, 4, 2006. Crossref

  8. Shiku Hiroshi, Importance of CD4+ Helper T-cells in Antitumor Immunity, International Journal of Hematology, 77, 5, 2003. Crossref

  9. Disis Mary L, Bernhard Helga, Jaffee Elizabeth M, Use of tumour-responsive T cells as cancer treatment, The Lancet, 373, 9664, 2009. Crossref

  10. Mitchell Duane A., Fecci Peter E., Sampson John H., Immunotherapy of malignant brain tumors, Immunological Reviews, 222, 1, 2008. Crossref

  11. Kennedy Richard, Celis Esteban, Multiple roles for CD4+T cells in anti-tumor immune responses, Immunological Reviews, 222, 1, 2008. Crossref

  12. Disis Mary L., Park Kyong Hwa, Immunomodulation of Breast Cancer via Tumor Antigen Specific Th1, Cancer Research and Treatment, 41, 3, 2009. Crossref

  13. Rajnavölgyi Éva, Lányi Árpád, , 87, 2003. Crossref

  14. Lee Kihyun, Min Hyun Jung, Jang Eun Jung, Hong Jeong-Ho, Hwang Eun Sook, In vivo tumor suppression activity by T cell-specific T-bet restoration, International Journal of Cancer, 127, 9, 2010. Crossref

  15. Sugiura Daisuke, Denda-Nagai Kaori, Takeda Kazuyoshi, Irimura Tatsuro, Organ microenvironment plays significant roles through Fas ligand in vaccine-induced CD4+ T cell dependent suppression of tumor growth at the orthotopic site, Cancer Science, 101, 9, 2010. Crossref

  16. Marshall Deana, Mitchell Duane A., Graner Michael W., Bigner Darell D., Immunotherapy of brain tumors, in Neuro-Oncology. Vol 104 HCN Series, 104, 2012. Crossref

  17. Sznurkowski Jacek Jan, Żawrocki Anton, Emerich Janusz, Biernat Wojciech, Prognostic Significance of CD4+and CD8+T Cell Infiltration Within Cancer Cell Nests in Vulvar Squamous Cell Carcinoma, International Journal of Gynecologic Cancer, 21, 4, 2011. Crossref

  18. Shimizu Keiji, Kuriyama Hideyuki, Kjaergaard Jorgen, Lee Walter, Tanaka Hiroshi, Shu Suyu, Comparative Analysis of Antigen Loading Strategies of Dendritic Cells for Tumor Immunotherapy, Journal of Immunotherapy, 27, 4, 2004. Crossref

  19. Wojtowicz Malgorzata E., Dunn Barbara K., Umar Asad, Immunologic approaches to cancer prevention—current status, challenges, and future perspectives, Seminars in Oncology, 43, 1, 2016. Crossref

  20. Wang Rong-Fu, The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity, Trends in Immunology, 22, 5, 2001. Crossref

  21. Sundberg Eric J., Sawicki Mark W., Southwood Scott, Andersen Peter S., Sette Alessandro, Mariuzza Roy A., Minor Structural Changes in a Mutated Human Melanoma Antigen Correspond to Dramatically Enhanced Stimulation of a CD4+ Tumor-infiltrating Lymphocyte Line, Journal of Molecular Biology, 319, 2, 2002. Crossref

  22. Lv Jizhou, Tao Ning, Wu Hao, Liu Xiaoman, Xu Xia, Xu Yingxin, Qin Zhihai, Selective expansion and enhanced anti-tumor effect of antigen-specific CD4+ T cells by retrovirus-mediated IL-15 expression, Protein & Cell, 2, 7, 2011. Crossref

  23. Mahnke Yolanda D, Schirrmacher Volker, A novel tumour model system for the study of long-term protective immunity and immune T cell memory, Cellular Immunology, 221, 2, 2003. Crossref

  24. Zhang Wenjing, Tian Xinli, Mumtahana Fidia, Jiao Jun, Zhang Teng, Croce Kimiko Della, Ma Daoxin, Kong Beihua, Cui Baoxia, The existence of Th22, pure Th17 and Th1 cells in CIN and Cervical Cancer along with their frequency variation in different stages of cervical cancer, BMC Cancer, 15, 1, 2015. Crossref

  25. Tamai Hidemasa, Watanabe Satoshi, Zheng Rongxiu, Deguchi Katsuya, Cohen Peter A., Koski Gary K., Shu Suyu, Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic–tumor hybrid vaccination and adoptive transfer of sensitized T cells, Clinical Immunology, 127, 1, 2008. Crossref

  26. Kaufman Howard L, Di Vito Joseph, Hörig Heidi, Immunotherapy for pancreatic cancer: current concepts, Hematology/Oncology Clinics of North America, 16, 1, 2002. Crossref

  27. Hayashi Takashi, Tanaka Hiroshi, Tanaka Junta, Wang Rongfu, Averbook Bruce J., Cohen Peter A., Shu Suyu, Immunogenicity and Therapeutic Efficacy of Dendritic–Tumor Hybrid Cells Generated by Electrofusion, Clinical Immunology, 104, 1, 2002. Crossref

  28. Tanaka Hiroshi, Shimizu Keiji, Hayashi Takashi, Shu Suyu, Therapeutic immune response induced by electrofusion of dendritic and tumor cells, Cellular Immunology, 220, 1, 2002. Crossref

  29. Fang Jinbo, Wang Guiyun, Yang Qiong, Song Jinna, Wang Ye, Wang Li, The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model, Vaccine, 23, 40, 2005. Crossref

  30. Soto Carolina M., Stone Jennifer D., Chervin Adam S., Engels Boris, Schreiber Hans, Roy Edward J., Kranz David M., MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR, Cancer Immunology, Immunotherapy, 62, 2, 2013. Crossref

  31. Kiniwa Yukiko, Li Jiang, Wang Mingjun, Sun Chuang, Lee Jeffrey E., Wang Rong-Fu, Wang Helen Y., Bai Xue-feng, Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells, PLOS ONE, 10, 5, 2015. Crossref

  32. Wang Rong-Fu, Melanoma antigens recognized by CD4+ T cells, in Tumor Antigens Recognized by T Cells and Antibodies, 2003. Crossref

  33. Visioni Anthony, Skitzki Joseph, Technical Considerations for the Generation of Adoptively Transferred T Cells in Cancer Immunotherapy, Cancers, 8, 9, 2016. Crossref

  34. Nocera Nadia F., Lee M. Catherine, De La Cruz Lucy M., Rosemblit Cinthia, Czerniecki Brian J., Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention, Frontiers in Pharmacology, 7, 2016. Crossref

  35. Li Xiao-Lin, Liu Yong-Yu, Knight David, Odaka Yoshinobu, Mathis J. Michael, Shi Runhua, Glass Jonathan, Zhang Qian-Jin, Unutmaz Derya, Effect of B7.1 Costimulation on T-Cell Based Immunity against TAP-Negative Cancer Can Be Facilitated by TAP1 Expression, PLoS ONE, 4, 7, 2009. Crossref

  36. Dasgupta Santanu, Bhattacharya-Chatterjee Malaya, O'Malley Bert W., Chatterjee Sunil K., Recombinant Vaccinia Virus Expressing Interleukin-2 Invokes Anti-tumor Cellular Immunity in an Orthotopic Murine Model of Head and Neck Squamous Cell Carcinoma, Molecular Therapy, 13, 1, 2006. Crossref

  37. McNeel Douglas G., Nguyen Lan D., Ellis William J., Higano Celestia S., Lange Paul H., Disis Mary L., Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 Phenotype can be detected in patients with prostate cancer, The Prostate, 47, 3, 2001. Crossref

  38. Bowers Jacob S., Nelson Michelle H., Majchrzak Kinga, Bailey Stefanie R., Rohrer Baerbel, Kaiser Andrew D.M., Atkinson Carl, Gattinoni Luca, Paulos Chrystal M., Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion, JCI Insight, 2, 5, 2017. Crossref

  39. Wang Bei, Zaidi Neeha, He Li-Zhen, Zhang Li, Kuroiwa Janelle MY, Keler Tibor, Steinman Ralph M, Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice, Breast Cancer Research, 14, 2, 2012. Crossref

  40. Su Zhen, Peluso Mario V., Raffegerst Silke H., Schendel Dolores J., Roskrow Marie A., Antigen Presenting Cells Transfected with LMP2a RNA Induce CD4 + LMP2a-specific Cytotoxic T Lymphocytes which Kill via a Fas-independent Mechanism, Leukemia & Lymphoma, 43, 8, 2002. Crossref

  41. Gholizadeh Zahra, Tavakkol-Afshari Jalil, Nikpoor Amin Reza, Jalali Seyed Amir, Jaafari Mahmoud Reza, Enhanced immune response induced by P5 HER2/neu-derived peptide-pulsed dendritic cells as a preventive cancer vaccine, Journal of Cellular and Molecular Medicine, 22, 1, 2018. Crossref

  42. Rojas Jos� Manuel, McArdle Stephanie E. B., Horton Roger B. V., Bell Matthew, Mian Shahid, Li Geng, Ali Selman A., Rees Robert C., Peptide immunisation of HLA-DR?transgenic mice permits the identification of a novel HLA-DR?1*0101? and HLA-DR?1*0401?restricted epitope from p53, Cancer Immunology, Immunotherapy, 54, 3, 2005. Crossref

  43. EVANS DEAN E., WEINBERG ANDREW D., BOOSTING T CELL COSTIMULATION IN CANCER: THE POSSIBILITIES SEEM ENDLESS, International Reviews of Immunology, 22, 2, 2003. Crossref

  44. Perez-Diez Ainhoa, Joncker Nathalie T., Choi Kyungho, Chan William F. N., Anderson Colin C., Lantz Olivier, Matzinger Polly, CD4 cells can be more efficient at tumor rejection than CD8 cells, Blood, 109, 12, 2007. Crossref

  45. Cohen Peter A., Shu Suyu, Finke James H., Principles of Antitumor Immunity and Tumor-Mediated Immunosuppression, in Melanoma, 2002. Crossref

  46. Lee Walter T., Dendritic Cell-Tumor Cell Fusion Vaccines, in Cell Fusion in Health and Disease, 713, 2011. Crossref

  47. Hutson Thomas E., Thakkar Snehal, Cohen Peter, Borden Ernest C., Interferons and Interleukin-2: Molecular Basis of Activity and Therapeutic Results, in Renal Cell Carcinoma, 2009. Crossref

  48. Muranski Pawel, Boni Andrea, Antony Paul A., Cassard Lydie, Irvine Kari R., Kaiser Andrew, Paulos Chrystal M., Palmer Douglas C., Touloukian Christopher E., Ptak Krzysztof, Gattinoni Luca, Wrzesinski Claudia, Hinrichs Christian S., Kerstann Keith W., Feigenbaum Lionel, Chan Chi-Chao, Restifo Nicholas P., Tumor-specific Th17-polarized cells eradicate large established melanoma, Blood, 112, 2, 2008. Crossref

  49. Kayashima Hiroto, Toshima Takeo, Okano Shinji, Taketomi Akinobu, Harada Noboru, Yamashita Yo-ichi, Tomita Yukihiro, Shirabe Ken, Maehara Yoshihiko, Intratumoral Neoadjuvant Immunotherapy Using IL-12 and Dendritic Cells Is an Effective Strategy To Control Recurrence of Murine Hepatocellular Carcinoma in Immunosuppressed Mice, The Journal of Immunology, 185, 1, 2010. Crossref

  50. Graziano Daniel F., Finn Olivera J., Tumor Antigens and Tumor Antigen Discovery, in Tumor Immunology and Cancer Vaccines, 123, 2005. Crossref

  51. Jensen Shawn M., Fox Bernard A., Tumor Immunology and Cancer Vaccines, in Tumor Immunology and Cancer Vaccines, 123, 2005. Crossref

  52. Cohen Peter A., Plautz Gregory E., Finke James H., Shu Suyu, Optimizing T-Cell Adoptive Immunotherapy to Overcome Tumor Evasion, in Cancer Immunotherapy at the Crossroads, 2004. Crossref

  53. Plautz Gregory E., Cohen Peter A., Weng David E., Shu Suyu, T-Cell Adoptive Immunotherapy, in Handbook of Cancer Vaccines, 2004. Crossref

  54. Cohen Peter A., Koski Gary K., Czerniecki Brian J., Bunting Kevin D., Fu Xin-Yuan, Wang Zhengqi, Zhang Wen-Jun, Carter Charles S., Awad Mohamed, Distel Christopher A., Nagem Hassan, Paustian Christopher C., Johnson Terrence D., Tisdale John F., Shu Suyu, STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells, Blood, 112, 5, 2008. Crossref

  55. Wang Li-Xin, Shu Suyu, Disis Mary L., Plautz Gregory E., Adoptive transfer of tumor-primed, in vitro–activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response, Blood, 109, 11, 2007. Crossref

  56. Faries Mark B., Bedrosian Isabelle, Xu Shuwen, Koski Gary, Roros James G., Moise Mirielle A., Nguyen Hung Q., Engels Friederike H. C., Cohen Peter A., Czerniecki Brian J., Calcium signaling inhibits interleukin-12 production and activates CD83+ dendritic cells that induce Th2 cell development, Blood, 98, 8, 2001. Crossref

  57. Gulubova M., Ananiev J., Ignatova M., Halacheva K., Pro-Tumor and Anti-Tumor Functions of IL-17 and of TH17 Cells in Tumor Microenvironment, Acta Medica Bulgarica, 43, 2, 2016. Crossref

  58. Stanton Sasha E, Disis Mary L, Designing vaccines to prevent breast cancer recurrence or invasive disease, Immunotherapy, 7, 2, 2015. Crossref

  59. KNUTSON K L, DISIS M L, IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion, Clinical and Experimental Immunology, 135, 2, 2004. Crossref

  60. Kalli Kimberly R., Krco Christopher J., Hartmann Lynn C., Goodman Karin, Maurer Matthew J., Yu Chao, Johnson Elliot M., Erskine Courtney L., Disis Mary L., Wettstein Peter J., Fikes John D., Beebe Melanie, Ishioka Glenn, Knutson Keith L., An HLA-DR–Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2–Specific Immunity in Patients with Cancer, Cancer Research, 68, 12, 2008. Crossref

  61. Park Kyong Hwa, Gad Ekram, Goodell Vivian, Dang Yushe, Wild Thayer, Higgins Doreen, Fintak Patty, Childs Jennifer, dela Rosa Corazon, Disis Mary L., Insulin-like Growth Factor–Binding Protein-2 Is a Target for the Immunomodulation of Breast Cancer, Cancer Research, 68, 20, 2008. Crossref

  62. D'Amico G, Bonamino M, Dander E, Marin V, Basso G, Balduzzi A, Biagi E, Biondi A, T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy, Leukemia, 20, 11, 2006. Crossref

  63. Dissanayake Samudra K., Thompson James A., Bosch Jacobus J., Clements Virginia K., Chen Peter W., Ksander Bruce R., Ostrand-Rosenberg Suzanne, Activation of Tumor-specific CD4+ T Lymphocytes by Major Histocompatibility Complex Class II Tumor Cell Vaccines, Cancer Research, 64, 5, 2004. Crossref

  64. Gao Y, Whitaker-Dowling P, Griffin J A, Bergman I, Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells, Cancer Gene Therapy, 19, 4, 2012. Crossref

  65. Ivanov Roman, Hagenbeek Anton, Ebeling Saskia, Towards immunogene therapy of hematological malignancies, Experimental Hematology, 34, 3, 2006. Crossref

  66. Sussman Jeffrey J., Parihar Robin, Winstead Karen, Finkelman Fred D., Prolonged Culture of Vaccine-Primed Lymphocytes Results in Decreased Antitumor Killing and Change in Cytokine Secretion, Cancer Research, 64, 24, 2004. Crossref

  67. Röhn Till A., Reitz Annette, Paschen Annette, Nguyen Xuan D., Schadendorf Dirk, Vogt Anne B., Kropshofer Harald, A Novel Strategy for the Discovery of MHC Class II–Restricted Tumor Antigens: Identification of a Melanotransferrin Helper T-Cell Epitope, Cancer Research, 65, 21, 2005. Crossref

  68. Yoshida Ayako, Maruyama Haruhiko, Kumagai Takashi, Amano Teruaki, Kobayashi Fumie, Wang Jinyan, Kuribayashi Kagemasa, Ohta Nobuo, Enhanced UV♀1 tumor growth in CBF1 mice infected with Schistosoma mansoni due to modulation of Th1-like responses, Parasitology International, 51, 2, 2002. Crossref

  69. Prabakaran Indira, Menon Chandrakala, Xu Shuwen, Gómez-Yafal Alicia, Czerniecki Brian J., Fraker Douglas L., Mature CD83+ dendritic cells infected with recombinant gp 100 vaccinia virus stimulate potent antimelanoma T cells, Annals of Surgical Oncology, 9, 4, 2002. Crossref

  70. Peng Liaomin, Krauss John C., Plautz Gregory E., Mukai Shigehiko, Shu Suyu, Cohen Peter A., T Cell-Mediated Tumor Rejection Displays Diverse Dependence Upon Perforin and IFN-γ Mechanisms That Cannot Be Predicted From In Vitro T Cell Characteristics, The Journal of Immunology, 165, 12, 2000. Crossref

  71. Novellino Luisa, Renkvist Nicolina, Rini Francesca, Mazzocchi Arabella, Rivoltini Licia, Greco Angela, Deho Paola, Squarcina Paola, Robbins Paul F., Parmiani Giorgio, Castelli Chiara, Identification of a Mutated Receptor-Like Protein Tyrosine Phosphatase κ as a Novel, Class II HLA-Restricted Melanoma Antigen, The Journal of Immunology, 170, 12, 2003. Crossref

  72. Plautz Gregory E., Mukai Shigehiko, Cohen Peter A., Shu Suyu, Cross-Presentation of Tumor Antigens to Effector T Cells Is Sufficient to Mediate Effective Immunotherapy of Established Intracranial Tumors, The Journal of Immunology, 165, 7, 2000. Crossref

  73. Kanaseki Takayuki, Ikeda Hideyuki, Takamura Yukio, Toyota Minoru, Hirohashi Yoshihiko, Tokino Takashi, Himi Tetsuo, Sato Noriyuki, Histone Deacetylation, But Not Hypermethylation, Modifies Class II Transactivator and MHC Class II Gene Expression in Squamous Cell Carcinomas, The Journal of Immunology, 170, 10, 2003. Crossref

  74. Peng Liaomin, Kjaergaard Jørgen, Plautz Gregory E., Weng David E., Shu Suyu, Cohen Peter A., Helper-Independent, L-Selectinlow CD8+ T Cells with Broad Anti-Tumor Efficacy Are Naturally Sensitized During Tumor Progression, The Journal of Immunology, 165, 10, 2000. Crossref

Próximos artigos

Identification of a novel five-gene prognostic model for laryngeal cancer associated with mitophagy using integrated bioinformatics analysis and experimental verification Dong Song, Lun Dong, Mei Wang, Xiaoping Gao Function of steroid receptor coactivators (SRCs) in T cells and cancers: Implications for cancer immunotherapy Wencan Zhang, Xu Cao, Hongmin Wu, Xiancai Zhong, Yun Shi, Zuoming Sun Electroacupuncture Alleviates Ischemic Stroke by Activating the mTOR/SREBP1 Pathway Jiawang Lang, Jianchang Luo, Luodan Wang, Wenbin Xu, Jie Jia, Zhipeng Zhao, Boxu Lang KIAA1429 induces the m6A modification of LINC01106 to enhance the malignancy of lung adenocarcinoma cell via JAK/STAT3 pathway Di Xu, Ziming Wang, Fajiu Li Effect of p-estrogen receptor at serine on its function and breast growth Yuan Liang, Junhui Qin, Tiancheng Ma, Tong Yang, Zhenyu Ke, Ruian Wang Mechanistic Insights into Tanshinone IIA in the Amelioration of Post-Thyroidectomy Hypoparathyroidism Xiaoyu Qian, Lin Li, Liang Chen, Chao Shen, Jian Tang MiRNA let-7d-5p alleviates inflammatory responses by targeting Map3k1 and inactivating ERK/p38 MAPK signaling in microglia Fan Fang, Cheng Chen Role of Natural Killer Cells as Cell-Based Immunotherapy in Oral Tumor Eradication and Differentiation Both In Vivo and In Vitro Kawaljit Kaur, Anahid Jewett The Current and Future States of Natural Killer Cell-Based Immunotherapy in Hepatocellular Carcinoma Tu Nguyen, Po-Chun Chen, Janet Pham, Kawaljit Kaur, Steven Raman, Anahid Jewett, Jason Chiang Phillygenin alleviated arthritis through the inhibition of NLRP3 inflammasome and Ferroptosis by AMPK Jianghui Wang, Shufang Ni, Kai Zheng, Yan Zhao, peihong zhang, Hong Chang The value of systemic immune-inflammation index and T cell subsets in the severity and prognosis of sepsis Hao Zhou Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach Muhammad Imran Qadir, Bilal Ahmed, Nadir Hussain Serum interleukin 6 and ferritin levels are the independent risk factors for pneumonia in elderly patients Hao Yuan, Jing Tian, Lu Wen Exploration of diagnostic markers associated with inflammation in chronic kidney disease (CKD) based on WGCNA and machine learning Qianjia Wu, Yang Yang, Chongze Lin Clinical significance of serum CTRP3 level in the prediction of cardiac dysfunction and intestinal mucosal barrier dysfunction in patients with severe acute pancreatitis Qiang Shao, Lin Sun The protective effect and mechanism of mild hypothermia on pig lung injury after cardiopulmonary resuscitation Jinlin Ren, Fangfang Zhu, Dongdong Sang, Mulin Cong, Shujuan Jiang Exploring mechanism of Zilongjin in treating lung adenocarcinoma based on network pharmacology combined with experimental verification Kang Zhang, Xiaoqun Chen Gastric Cancer Immune Subtypes and Prognostic Modeling: Insights from Aging-Related Genes Analysis Jian Shen, Minzhe Li Effects of different doses of dexmedetomidine on the prevention of postoperative sleep disturbance and serum neurotransmitter level in patients under general anesthesia Huifei Lu, Fei He, Ying Huang, Zhongliang Wei Identification of key ubiquitination-related genes and their associated with immune infiltration in osteoarthritis based on mRNA-miRNA network Dalu Yuan, Hailiang Shen, Lina Bai, Menglin Li, Qiujie Ye Diagnostic and Prognostic value of peripheral neutrophil CD64 index in elderly patients with community-acquired pneumonia Yan Li, Jing Zhang, Suhang Wang, Jie Cao Identification of Metabolism-Related Prognostic Biomarkers and Immune Features of Head and Neck Squamous Cell Carcinoma Rongjin Zhou, Junguo Wang Downregulation of miR-503-5p promotes the development of pancreatic cancer via targeting cyclin E2 Fei Li, Ying-pei Ling, Pan Wang, Shi-cheng Gu, Hao Jiang, Jie Zhu
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain